Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II randomized double-blind sham-controlled dose-escalation study of ZM-02 Injection in advanced retinitis pigmentosa
CTR20263907Phase 2Active
- Sponsor
- Augelux Therapeutics
- Start
- Oct 2026
- Modality
- Gene Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of ZM-02 in retinitis pigmentosa (RP), sponsored by Augelux Therapeutics. Started Oct 2026; status: active.
02
Drugs
ZM-02
03
Conditions
retinitis pigmentosa (RP)
Beyond the preview
Go deeper on CTR20263907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263907.